A prospective randomised controlled trial of management of recurrent nosebleeds in children: antiseptic cream alone versus antiseptic cream with nasal cautery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-006089-32-GB

Enrollment

216

Registered

2006-03-03

Start date

2006-05-04

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Paediatric Epistaxis

Interventions

Trade Name: AVOCA Caustic Applicator Product Name: Caustic Applicator Pharmaceutical Form: Nasal stick Trade Name: Naseptin Product Nam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 1-14 with a history of repeated epistaxis with at lease 1 episode in the previous 4 weeks prior to attending the ENT clinic. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Known bleeding disorders. Allergy to peanuts, peanut oil, neomycin or chlorhexidine (these are contained in the Naseptin cream). Other causes of nose bleeding eg. tumour.

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether silver nitrate cautery has any therapeutic effect in addition to 4 weeks of Naseptin cream in the management of recurrent paediatric epistaxis in patients with visible vessels in their nasal septum.;Secondary Objective: Not applicable.;Primary end point(s): Proportion of children with no nose bleeds in a 4 week period prior to clinical review.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026